RESULTS OF SURGICAL TREATMENT OF IOL DISLOCATION

Purpose.  The analysis of clinical results  in  the  replacement  of dislocated posterior chamber IOL with capsular bag (CB) to the iridovitreal IOL RSP-3 (Russia) via a scleral-corneal tunnel incision.Material and methods. The study included 26 patients (26 pseudophakic eyes) with a dislocation of the IOL capsular bag (CB) complex after the previously performed phacoemulsification  (PE), who underwent a removal of IOL with CB through a scleral-corneal tunnel incision with the following implantation of irido-vitreal  IOL RSP-3.Besides the standard  examination, the patients  underwent a corneal endothelium count test before operation, at discharge, 1, 6 and 12 months later.Results. The dislocated IOL occupied from 20 to 50% of the pupil area causing complaints on a low visual acuity (VA), ineffectiveness of spectacle correction and binocular or monocular diplopia.All operations passed uneventfully. The early postoperative period was non-reactive in the majority of cases.It was possible intraoperatively to preserve a stable depth of anterior chamber using viscoelastic Discovisc  (Alcon), thus, avoiding a rupture of anterior hyaloid membrane of vitreous body and damage of corneal endothelium.The best corrected VA (BCVA) increased from 0.32±0.05 to 0.81±0.1 in the dynamics of postoperative period, induced astigmatism indexes decreased  in  the  absence  of negative dynamics of endothelium cell density (the loss of corneal endothelium cells averaged 4.7% from the initial level).Conclusion. The used surgical method of replacement of the dislocated IOL-CB complex after the PE of senile cataract  to the iridovitreal IOL  RSP-3 via the  scleral-corneal tunnel minimizes  the  risks of  intra- and  post-operative complications. The advantages  of  this technology are the safety, low indexes of induced corneal astigmatism, and high and stable visual effect

Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

Aspirin reduces cardiovascular events in patients with coronary artery disease (CAD), but studies report a highly variable response to aspirin, often referred to as 'aspirin low-responsiveness'. We investigated whether 75 mg of daily non-enteric coated aspirin would completely inhibit the platelet cyclooxygenase-1 activity to a comparable extent in healthy individuals and stable CAD patients